Hypoglycaemia due to insulinoma, whether the tumour is advanced or not at the time of diagnosis may be difficult to treat. Profound and recurrent hypoglycaemia may be an important clinical problem for the patient, impacting on daily activities, resulting in recurrent admissions or even preventing safe discharge from an inpatient setting. In this talk we will review the options available for treating hypoglycaemia due to insulinoma, considering the strengths and limitations of these therapies and examining the evidence base for their use.
04 Dec 2017
UK and Ireland Neuroendocrine Tumour Society